Anthony D. Ho

Active 1988–2024

159
Papers
29,717
Citations
96
h-index
158
i10-index

Citations

Citations per year for Anthony D. Ho1979: 2 citations1983: 1 citations1986: 1 citations1989: 2 citations1990: 1 citations1991: 5 citations1992: 10 citations1993: 11 citations1994: 9 citations1995: 9 citations1996: 7 citations1997: 3 citations1998: 9 citations1999: 27 citations2000: 44 citations2001: 48 citations2002: 54 citations2003: 76 citations2004: 82 citations2005: 124 citations2006: 117 citations2007: 153 citations2008: 204 citations2009: 247 citations2010: 296 citations2011: 373 citations2012: 343 citations2013: 292 citations2014: 326 citations2015: 276 citations2016: 267 citations2017: 279 citations2018: 269 citations2019: 905 citations2020: 1,075 citations2021: 889 citations2022: 646 citations2023: 471 citations2024: 631 citations2025: 278 citations2026: 4 citations1980–1982: no citations, so these years are not shown1984–1985: no citations, so these years are not shown1987–1988: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,259 citing papers, 25.3% of this breakdownGermany: 1,361 citing papers, 10.6% of this breakdownUnited Kingdom: 893 citing papers, 6.9% of this breakdownChina: 865 citing papers, 6.7% of this breakdownItaly: 796 citing papers, 6.2% of this breakdownFrance: 587 citing papers, 4.5% of this breakdownCanada: 384 citing papers, 3% of this breakdownSpain: 383 citing papers, 3% of this breakdownNetherlands: 367 citing papers, 2.8% of this breakdownSwitzerland: 337 citing papers, 2.6% of this breakdownAustralia: 306 citing papers, 2.4% of this breakdownJapan: 288 citing papers, 2.2% of this breakdown
0%25.3%Other 23.8%

Fields

  • Medicine66.8%
  • Biochemistry, Genetics and Molecular Biology23.7%
  • Immunology and Microbiology5.4%
  • Engineering1%
  • Neuroscience0.8%
  • Physics and Astronomy0.5%
  • Other1.8%

Topics

  • Mesenchymal stem cell research5.2%
  • Lymphoma Diagnosis and Treatment4.6%
  • Acute Myeloid Leukemia Research3.1%
  • Multiple Myeloma Research and Treatments3.1%
  • Chronic Lymphocytic Leukemia Research3.1%
  • CAR-T cell therapy research2.7%
  • Other78.2%

Coauthors

All papers

Open in search
  1. Human haematopoietic stem cell lineage commitment is a continuous process

    Authors: , , , , , , , , , , , , , , , , - Nature Cell Biology 2017 cited by 928

  2. BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Anthony D. Ho, Jeroen Krijgsveld, Bernhard Radlwimmer, Andreas Trumpp - Nature 2017 cited by 353

  3. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis

    Authors: , , , , , , , , , , - Blood 2014 cited by 503

  4. Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Minh Diem Vu - Cancer Cell 2017 cited by 312

  5. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2008 cited by 1,135

  6. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Christiane Falge, Lothar Kanz, Stephan Kremers, Andreas Burchert, Michael Kneba, Frank Stegelmann, Claus-Henning Köhne, H. W. Lindemann, Cornelius F. Waller, M. Pfreundschuh, Karsten Spiekermann, Wolfgang E. Berdel, Lothar Müller, Matthias Edinger, Jiřı́ Mayer, Dietrich W. Beelen, Martin Bentz, Hartmut Link, Bernd Hertenstein, Roland J. Fuchs, Martin Wernli, Frank Schlegel, Rudolf Schlag, Maike de Wit, Lorenz Trümper, Holger Hebart, Markus Hahn, Jörg Thomalla, Christof Scheid, Philippe Schafhausen, Walter Verbeek, Michael J. Eckart, W. Gaßmann, Antonio Pezzutto, Michael Schenk, Peter Brossart, Thomas Geer, Stephan Bildat, E. Schäfer, Andreas Hochhaus, Joerg Hasford - Leukemia 2017 cited by 339

  7. Replicative Senescence of Mesenchymal Stem Cells: A Continuous and Organized Process

    Authors: , , , , , , , , , , - PLoS ONE 2008 cited by 1,122

  8. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group

    Authors: , , , , , , , , , - Blood 2010 cited by 592

  9. DNA methylation changes during long-term in vitro cell culture are caused by epigenetic drift

    Authors: , , , , , , , , , , , , , , , , , - Communications Biology 2021 cited by 82

  10. Aging and Replicative Senescence Have Related Effects on Human Stem and Progenitor Cells

    Authors: , , , , , , , , , , , - PLoS ONE 2009 cited by 479

  11. Two-stage Exchange Arthroplasty for Infected Total Knee Arthroplasty: Predictors of Failure

    Authors: , , , , - Clinical Orthopaedics and Related Research 2011 cited by 362

  12. Regulation of NK Cell Function by Human Granulocyte Arginase

    Authors: , , , , , , , - The Journal of Immunology 2009 cited by 138

  13. Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2018 cited by 250

  14. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

    Authors: , , , , , , , , , , , , , , , - Journal of Clinical Oncology 1998 cited by 2,759

  15. Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood

    Authors: , , , , , , , , , , - Experimental Hematology 2005 cited by 1,255

  16. AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis

    Authors: , , , , , , , , - Blood 2017 cited by 137

  17. Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Denise Wolleschak, Monika Brüggemann, Simon Haas, Anthony D. Ho, Carsten Müller‐Tidow, Peter Dreger, Michael Schmitt - Journal of Hematology & Oncology 2023 cited by 36

  18. Drug-perturbation-based stratification of blood cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kwang Seok Lee, Joe Lewis, Kerstin Putzker, Christoph Lutz, Davide Rossi, Andriy Mokhir, Thomas Oellerich, Katja Zirlik, Marco Herling, Florence Nguyen-Khac, Christoph Plass, Emma Andersson, Satu Mustjoki, Christof von Kalle, Anthony D. Ho, Manfred Hensel, Jan Dürig, Ingo Ringshausen, Marc Zapatka, Wolfgang Huber, Thorsten Zenz - Journal of Clinical Investigation 2017 cited by 155

  19. VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma

    Authors: , , , , , , , , , , , , , , , , , - British Journal of Cancer 2008 cited by 400

  20. Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients

    Authors: , , , , , , , - Blood 2011 cited by 248

  21. Quantitative proteomics reveals specific metabolic features of acute myeloid leukemia stem cells

    Authors: , , , , , , , , , , , , , , , , , , , , - Blood 2020 cited by 91

  22. DNA methylation pattern changes upon long‐term culture and aging of human mesenchymal stromal cells

    Authors: , , , , , , - Aging Cell 2009 cited by 415

  23. Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients

    Authors: , , , , , , , , , , , , , , , - Frontiers in Immunology 2018 cited by 99

  24. Evaluation of platelet-rich plasma as a treatment for androgenetic alopecia: A randomized controlled trial

    Authors: , , , , - Journal of the American Academy of Dermatology 2020 cited by 83